TPST | Tempest Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.7012 - 0.7540
52 Week Range	0.6990 - 6.00
Beta	-2.94
Implied Volatility	343.59%
IV Rank	94.08%
Day's Volume	1,455,742
Average Volume	3,617,050
Shares Outstanding	43,642,100
Market Cap	31,055,718
Sector	Healthcare
Industry	Biotechnology
IPO Date	2012-11-12

Valuation
Profitability
Growth
Health
P/E Ratio	-0.47
Forward P/E Ratio	N/A
EPS	-1.53
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	17
Country	USA
Website	TPST

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

TPST's peers: APRE, NTRB, CADL, PTIX, COCP, CYCC, FBIOP, FBRX, ICCC, IKT, INDP, MRKR, MTEM, NNVC, RNXT, SRZN, SVRA, RZLT, CMRA, SANA, OLMA, CGEM, LIFE, ZNTL, LYEL, GLUE, THRX, RVMD, ZIVO, IKNA, CBIO, AKTX, ARMP, ANEB, SCPS, PCSA, VTGN, XCUR, LSTA, MLEC, GDTC

*Chart delayed

Analyzing fundamentals for TPST we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see TPST Fundamentals page.

Watching at TPST technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TPST Technicals page.